{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:06:34Z","timestamp":1779062794236,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81760276"],"award-info":[{"award-number":["81760276"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Innovation and Entrepreneurship Fund of Qinghai University","award":["CXCY202408"],"award-info":[{"award-number":["CXCY202408"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-46162-0","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:19:12Z","timestamp":1775020752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Co-delivery of cisplatin and Bmi1 siRNA via nanocapsules overcomes chemoresistance in ovarian cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Mengbin","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junru","family":"Heng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunlong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"46162_CR1","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","volume":"4","author":"PA Konstantinopoulos","year":"2023","unstructured":"Konstantinopoulos, P. A. & Matulonis, U. A. Clinical and translational advances in ovarian cancer therapy. Nat. Cancer. 4, 1239\u20131257. https:\/\/doi.org\/10.1038\/s43018-023-00617-9 (2023).","journal-title":"Nat. Cancer"},{"key":"46162_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jclinepi.2022.10.005","volume":"152","author":"F Kuehne","year":"2022","unstructured":"Kuehne, F. et al. Causal analyses with target trial emulation for real-world evidence removed large self-inflicted biases: Systematic bias assessment of ovarian cancer treatment effectiveness. J. Clin. Epidemiol. 152, 269\u2013280. https:\/\/doi.org\/10.1016\/j.jclinepi.2022.10.005 (2022).","journal-title":"J. Clin. Epidemiol."},{"key":"46162_CR3","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jama.2025.9495","volume":"334","author":"G Caruso","year":"2025","unstructured":"Caruso, G., Weroha, S. J. & Cliby, W. Ovarian cancer: A review. JAMA 334, 1278\u20131291. https:\/\/doi.org\/10.1001\/jama.2025.9495 (2025).","journal-title":"JAMA"},{"key":"46162_CR4","doi-asserted-by":"publisher","first-page":"114205","DOI":"10.1016\/j.ejmech.2022.114205","volume":"232","author":"M Song","year":"2022","unstructured":"Song, M., Cui, M. & Liu, K. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur. J. Med. Chem. 232, 114205. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114205 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"46162_CR5","doi-asserted-by":"publisher","first-page":"113969","DOI":"10.1016\/j.addr.2021.113969","volume":"178","author":"Z Wang","year":"2021","unstructured":"Wang, Z., Meng, F. & Zhong, Z. Emerging targeted drug delivery strategies toward ovarian cancer. Adv. Drug Deliv. Rev. 178, 113969. https:\/\/doi.org\/10.1016\/j.addr.2021.113969 (2021).","journal-title":"Adv. Drug Deliv Rev."},{"key":"46162_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pathol-012615-044438","volume":"11","author":"D Nassar","year":"2016","unstructured":"Nassar, D. & Blanpain, C. Cancer stem cells: Basic concepts and therapeutic implications. Annu. Rev. Pathol. 11, 47\u201376. https:\/\/doi.org\/10.1146\/annurev-pathol-012615-044438 (2016).","journal-title":"Annu. Rev. Pathol."},{"key":"46162_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drup.2015.11.003","volume":"24","author":"JA Ferreira","year":"2016","unstructured":"Ferreira, J. A. et al. Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation. Drug Resist. Updat. 24, 34\u201354. https:\/\/doi.org\/10.1016\/j.drup.2015.11.003 (2016).","journal-title":"Drug Resist. Updat"},{"key":"46162_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12943-017-0638-3","volume":"16","author":"M Lupia","year":"2017","unstructured":"Lupia, M. & Cavallaro, U. Ovarian cancer stem cells: Still an elusive entity? Mol. Cancer. 16, 64. https:\/\/doi.org\/10.1186\/s12943-017-0638-3 (2017).","journal-title":"Mol. Cancer"},{"key":"46162_CR9","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.gendis.2022.02.006","volume":"9","author":"A Dey","year":"2022","unstructured":"Dey, A. et al. Targeting BMI1 mitigates chemoresistance in ovarian cancer. Genes Dis. 9, 1415\u20131418. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.006 (2022).","journal-title":"Genes Dis."},{"key":"46162_CR10","doi-asserted-by":"publisher","unstructured":"Xu, J., Li, L., Shi, P., Cui, H. & Yang, L. The crucial roles of Bmi-1 in cancer: Implications in pathogenesis, metastasis, drug resistance, and targeted therapies. Int. J. Mol. Sci. 23 https:\/\/doi.org\/10.3390\/ijms23158231 (2022).","DOI":"10.3390\/ijms23158231"},{"key":"46162_CR11","doi-asserted-by":"publisher","unstructured":"Lozneanu, L. et al. BMI-1 expression heterogeneity in endometriosis-related and non-endometriotic ovarian carcinoma. Int. J. Mol. Sci. 22. https:\/\/doi.org\/10.3390\/ijms22116082 (2021).","DOI":"10.3390\/ijms22116082"},{"issue":"e236","key":"46162_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.stem.2020.06.022","volume":"27","author":"L Jia","year":"2020","unstructured":"Jia, L., Zhang, W. & Wang, C. Y. BMI1 Inhibition eliminates residual cancer stem cells after PD1 blockade and activates antitumor immunity to prevent metastasis and relapse. Cell. Stem Cell. 27 (e236), 238\u2013253. https:\/\/doi.org\/10.1016\/j.stem.2020.06.022 (2020).","journal-title":"Cell. Stem Cell."},{"key":"46162_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/15548627.2016.1147670","volume":"12","author":"A Dey","year":"2016","unstructured":"Dey, A. et al. Inhibition of BMI1 induces autophagy-mediated necroptosis. Autophagy 12, 659\u2013670. https:\/\/doi.org\/10.1080\/15548627.2016.1147670 (2016).","journal-title":"Autophagy"},{"key":"46162_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13046-017-0644-8","volume":"36","author":"Q Peng","year":"2017","unstructured":"Peng, Q. et al. Autophagy maintains the stemness of ovarian cancer stem cells by FOXA2. J. Exp. Clin. Cancer Res. 36, 171. https:\/\/doi.org\/10.1186\/s13046-017-0644-8 (2017).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"46162_CR15","doi-asserted-by":"publisher","first-page":"e2210787","DOI":"10.1002\/adma.202210787","volume":"35","author":"Y Wu","year":"2023","unstructured":"Wu, Y. et al. A physiologically responsive nanocomposite hydrogel for treatment of head and neck squamous cell carcinoma via proteolysis-targeting chimeras enhanced immunotherapy. Adv. Mater. 35, e2210787. https:\/\/doi.org\/10.1002\/adma.202210787 (2023).","journal-title":"Adv. Mater."},{"key":"46162_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13048-018-0406-z","volume":"11","author":"Q Zhao","year":"2018","unstructured":"Zhao, Q. et al. Role of BMI1 in epithelial ovarian cancer: Investigated via the CRISPR\/Cas9 system and RNA sequencing. J. Ovarian Res. 11, 31. https:\/\/doi.org\/10.1186\/s13048-018-0406-z (2018).","journal-title":"J. Ovarian Res."},{"key":"46162_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang, L. et al. Targeting cancer stem cell pathways for cancer therapy. Signal. Transduct. Target. Ther. 5, 8. https:\/\/doi.org\/10.1038\/s41392-020-0110-5 (2020).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"46162_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.tips.2023.11.006","volume":"45","author":"Y Liu","year":"2024","unstructured":"Liu, Y. & Wang, H. Biomarkers and targeted therapy for cancer stem cells. Trends Pharmacol. Sci. 45, 56\u201366. https:\/\/doi.org\/10.1016\/j.tips.2023.11.006 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"46162_CR19","doi-asserted-by":"publisher","first-page":"12237","DOI":"10.1021\/acsnano.5c00322","volume":"19","author":"Y Wu","year":"2025","unstructured":"Wu, Y. et al. A hybrid manganese nanoparticle simultaneously eliminates cancer stem cells and activates STING pathway to potentiate cancer immunotherapy. ACS Nano. 19, 12237\u201312252. https:\/\/doi.org\/10.1021\/acsnano.5c00322 (2025).","journal-title":"ACS Nano"},{"key":"46162_CR20","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.7150\/thno.9423","volume":"4","author":"T Yang","year":"2014","unstructured":"Yang, T. et al. Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo. Theranostics 4, 1096\u20131111. https:\/\/doi.org\/10.7150\/thno.9423 (2014).","journal-title":"Theranostics"},{"key":"46162_CR21","doi-asserted-by":"publisher","first-page":"9896","DOI":"10.1021\/nn403606m","volume":"7","author":"S Guo","year":"2013","unstructured":"Guo, S. et al. Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano. 7, 9896\u20139904. https:\/\/doi.org\/10.1021\/nn403606m (2013).","journal-title":"ACS Nano"},{"key":"46162_CR22","doi-asserted-by":"publisher","first-page":"e2000416","DOI":"10.1002\/adma.202000416","volume":"32","author":"Y Zou","year":"2020","unstructured":"Zou, Y. et al. Single siRNA nanocapsules for effective siRNA brain delivery and glioblastoma treatment. Adv. Mater. 32, e2000416. https:\/\/doi.org\/10.1002\/adma.202000416 (2020).","journal-title":"Adv. Mater."},{"key":"46162_CR23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.26599\/nbe.2024.9290086","volume":"16","author":"H Yan","year":"2024","unstructured":"Yan, H. et al. Preparation of Bmi-1-siRNA lipid nanoparticles and effects in gastric cancer. Nano Biomed. Eng. 16, 416\u2013428. https:\/\/doi.org\/10.26599\/nbe.2024.9290086 (2024).","journal-title":"Nano Biomed. Eng."},{"key":"46162_CR24","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.26355\/eurrev_201905_17787","volume":"23","author":"XL Zhang","year":"2019","unstructured":"Zhang, X. L. et al. MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1. Eur. Rev. Med. Pharmacol. Sci. 23, 3635\u20133644. https:\/\/doi.org\/10.26355\/eurrev_201905_17787 (2019).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"46162_CR25","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41419-024-07075-w","volume":"15","author":"T Wen","year":"2024","unstructured":"Wen, T. et al. SOX4-BMI1 axis promotes non-small cell lung cancer progression and facilitates angiogenesis by suppressing ZNF24. Cell. Death Dis. 15, 698. https:\/\/doi.org\/10.1038\/s41419-024-07075-w (2024).","journal-title":"Cell. Death Dis."},{"key":"46162_CR26","doi-asserted-by":"publisher","first-page":"102077","DOI":"10.1016\/j.xcrm.2025.102077","volume":"6","author":"Z Qin","year":"2025","unstructured":"Qin, Z. et al. Co-targeting BMI1 and MYC to eliminate cancer stem cells in squamous cell carcinoma. Cell. Rep. Med. 6, 102077. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102077 (2025).","journal-title":"Cell. Rep. Med."},{"key":"46162_CR27","doi-asserted-by":"publisher","unstructured":"Hu, J. et al. BTF3 sustains cancer stem-like phenotype of prostate cancer via stabilization of BMI1. J. Exp. Clin. Cancer Res. 38. https:\/\/doi.org\/10.1186\/s13046-019-1222-z (2019).","DOI":"10.1186\/s13046-019-1222-z"},{"key":"46162_CR28","doi-asserted-by":"publisher","first-page":"22082","DOI":"10.1021\/acsami.2c01959","volume":"14","author":"A Zakharova","year":"2022","unstructured":"Zakharova, A., Iqbal, M. W., Madadian, E. & Simakov, D. S. A. Reverse microemulsion-synthesized high-surface-area Cu\/gamma-Al(2)O(3) catalyst for CO(2) conversion via reverse water gas shift. ACS Appl. Mater. Interfaces 14, 22082\u201322094. https:\/\/doi.org\/10.1021\/acsami.2c01959 (2022).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"46162_CR29","doi-asserted-by":"publisher","first-page":"8336","DOI":"10.1021\/la049137j","volume":"20","author":"RP Bagwe","year":"2004","unstructured":"Bagwe, R. P., Yang, C., Hilliard, L. R. & Tan, W. Optimization of dye-doped silica nanoparticles prepared using a reverse microemulsion method. Langmuir 20, 8336\u20138342. https:\/\/doi.org\/10.1021\/la049137j (2004).","journal-title":"Langmuir"},{"key":"46162_CR30","doi-asserted-by":"publisher","first-page":"13332","DOI":"10.1021\/acsami.6b03881","volume":"8","author":"W Zhang","year":"2016","unstructured":"Zhang, W. et al. Co-Delivery of cisplatin prodrug and chlorin e6 by mesoporous silica nanoparticles for chemo-photodynamic combination therapy to combat drug resistance. ACS Appl. Mater. Interfaces 8, 13332\u201313340. https:\/\/doi.org\/10.1021\/acsami.6b03881 (2016).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"46162_CR31","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.apsb.2023.08.027","volume":"14","author":"H Liu","year":"2024","unstructured":"Liu, H. et al. Unlocking the potential of amorphous calcium carbonate: A star ascending in the realm of biomedical application. Acta Pharm. Sin B. 14, 602\u2013622. https:\/\/doi.org\/10.1016\/j.apsb.2023.08.027 (2024).","journal-title":"Acta Pharm. Sin B"},{"key":"46162_CR32","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041532","author":"Z Li","year":"2024","unstructured":"Li, Z., Munim, M. B., Sharygin, D. A. & Bevis, B. J. Vander Heiden, M. G. Understanding the Warburg effect in cancer. Cold Spring Harb. Perspect. Med. https:\/\/doi.org\/10.1101\/cshperspect.a041532 (2024).","journal-title":"Cold Spring Harb Perspect. Med."},{"key":"46162_CR33","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.7150\/thno.103636","volume":"15","author":"X Shao","year":"2025","unstructured":"Shao, X. et al. Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy. Theranostics 15, 1689\u20131714. https:\/\/doi.org\/10.7150\/thno.103636 (2025).","journal-title":"Theranostics"},{"key":"46162_CR34","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.7150\/thno.104858","volume":"15","author":"C Sun","year":"2025","unstructured":"Sun, C. et al. Targeting platinum-resistant ovarian cancer by disrupting histone and RAD51 lactylation. Theranostics 15, 3055\u20133075. https:\/\/doi.org\/10.7150\/thno.104858 (2025).","journal-title":"Theranostics"},{"key":"46162_CR35","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869\u20131883. https:\/\/doi.org\/10.1038\/onc.2011.384 (2012).","journal-title":"Oncogene"},{"key":"46162_CR36","doi-asserted-by":"publisher","unstructured":"Zhang, H. et al. cAMP-PKA\/EPAC signaling and cancer: The interplay in tumor microenvironment. J. Hematol. Oncol. 17 https:\/\/doi.org\/10.1186\/s13045-024-01524-x (2024).","DOI":"10.1186\/s13045-024-01524-x"},{"key":"46162_CR37","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/mt.2015.28","volume":"23","author":"AL Fritz","year":"2015","unstructured":"Fritz, A. L., Adil, M. M., Mao, S. R. & Schaffer, D. V. cAMP and EPAC signaling functionally replace OCT4 during induced pluripotent stem cell reprogramming. Mol. Ther. 23, 952\u2013963. https:\/\/doi.org\/10.1038\/mt.2015.28 (2015).","journal-title":"Mol. Ther."},{"key":"46162_CR38","doi-asserted-by":"publisher","first-page":"778","DOI":"10.7150\/thno.29964","volume":"9","author":"M Satpathy","year":"2019","unstructured":"Satpathy, M. et al. Targeted drug delivery and image-guided therapy of heterogeneous ovarian cancer using HER2-targeted theranostic nanoparticles. Theranostics 9, 778\u2013795. https:\/\/doi.org\/10.7150\/thno.29964 (2019).","journal-title":"Theranostics"},{"key":"46162_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/onc.2008.374","volume":"28","author":"T Baba","year":"2009","unstructured":"Baba, T. et al. Epigenetic regulation of CD133 and tumorigenicity of CD133\u2009+\u2009ovarian cancer cells. Oncogene 28, 209\u2013218. https:\/\/doi.org\/10.1038\/onc.2008.374 (2009).","journal-title":"Oncogene"},{"key":"46162_CR40","doi-asserted-by":"publisher","first-page":"6565","DOI":"10.1158\/0008-5472.CAN-09-0913","volume":"69","author":"CP Masamha","year":"2009","unstructured":"Masamha, C. P. & Benbrook, D. M. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 69, 6565\u20136572. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-0913 (2009).","journal-title":"Cancer Res."},{"key":"46162_CR41","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.phymed.2007.03.006","volume":"14","author":"P Limtrakul","year":"2007","unstructured":"Limtrakul, P., Siwanon, S., Yodkeeree, S. & Duangrat, C. Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells. Phytomedicine 14, 381\u2013389. https:\/\/doi.org\/10.1016\/j.phymed.2007.03.006 (2007).","journal-title":"Phytomedicine"},{"key":"46162_CR42","doi-asserted-by":"publisher","unstructured":"Chen, D. et al. Targeting BMI1(+) cancer stem cells overcomes chemoresistance and inhibits metastases in squamous cell carcinoma. Cell Stem Cell 20, 621\u2013634 (2017). https:\/\/doi.org\/10.1016\/j.stem.2017.02.003","DOI":"10.1016\/j.stem.2017.02.003"},{"key":"46162_CR43","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-017-0617-8","volume":"16","author":"S Banerjee Mustafi","year":"2017","unstructured":"Banerjee Mustafi, S. et al. BMI1, a new target of CK2alpha. Mol. Cancer 16, 56. https:\/\/doi.org\/10.1186\/s12943-017-0617-8 (2017).","journal-title":"Mol. Cancer"},{"key":"46162_CR44","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1158\/0008-5472.CAN-17-1171","volume":"77","author":"Correction","year":"2017","unstructured":"Correction Chromosome instability modulated by BMI1-AURKA signaling drives progression in head and neck cancer. Cancer Res. 77, 3125\u20133126. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1171 (2017).","journal-title":"Cancer Res."},{"key":"46162_CR45","doi-asserted-by":"publisher","first-page":"23405","DOI":"10.1021\/acsnano.3c04636","volume":"17","author":"M Zhu","year":"2023","unstructured":"Zhu, M. et al. BMI1 silencing liposomes suppress postradiotherapy cancer stemness against radioresistant hepatocellular carcinoma. ACS Nano. 17, 23405\u201323421. https:\/\/doi.org\/10.1021\/acsnano.3c04636 (2023).","journal-title":"ACS Nano"},{"key":"46162_CR46","doi-asserted-by":"publisher","first-page":"114028","DOI":"10.1016\/j.jconrel.2025.114028","volume":"385","author":"JD Berezowitz","year":"2025","unstructured":"Berezowitz, J. D. & Givens, B. E. Nanocarrier drug delivery systems for gynecological cancer therapeutics. J. Control Rel. 385, 114028. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114028 (2025).","journal-title":"J. Control Release"},{"key":"46162_CR47","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1016\/j.apsb.2022.08.013","volume":"12","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Smart drug delivery systems for precise cancer therapy. Acta Pharm. Sin B. 12, 4098\u20134121. https:\/\/doi.org\/10.1016\/j.apsb.2022.08.013 (2022).","journal-title":"Acta Pharm. Sin B"},{"key":"46162_CR48","doi-asserted-by":"publisher","first-page":"9351","DOI":"10.2147\/IJN.S478313","volume":"19","author":"Q Lin","year":"2024","unstructured":"Lin, Q. et al. Advancing ovarian cancer therapeutics: The role of targeted drug delivery systems. Int. J. Nanomed. 19, 9351\u20139370. https:\/\/doi.org\/10.2147\/IJN.S478313 (2024).","journal-title":"Int. J. Nanomed."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46162-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46162-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46162-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T23:33:54Z","timestamp":1779060834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46162-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46162"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46162-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were conducted in accordance with the ARRIVE guidelines. All experimental procedures were approved by the Committee on Ethical Animal Experiments at Qinghai University Affiliated Hospital (The Clinical Medical School) and performed in compliance with relevant institutional regulations(Approval number: P-SL-2024-002).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Institutional Review Board"}}],"article-number":"15302"}}